You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Algorithm Performance Evaluation with Low Sample Size
SBC: Signature Research, Inc. Topic: NGA20C001The team of Signature Research, Inc. and Michigan Technological University will develop and demonstrate methods and metrics to evaluate the performance of machine learning-based computer vision algorithms with low numbers of samples of labeled EO imagery. We will use the existing xView panchromatic dataset to demonstrate a proof-of-concept set of tools. If successful, in Phase II, we will extend t ...
STTR Phase I 2021 Department of DefenseNational Geospatial-Intelligence Agency -
Eye-readable Solution-based Dye Displacement Probe for Large-area Detection of Opioids
SBC: INTELLIGENT OPTICAL SYSTEMS INC Topic: CBD20AT001Intelligent Optical Systems, Inc., in collaboration with Bowling Green State University, proposes to develop a field-rugged, eye-readable indicating spray solution that can immediately detect synthetic opioids over a large area of contamination (i.e., military vehicles, individual protective equipment, clandestine labs, etc.). The proposed chemosensor in a spray solution format will detect multipl ...
STTR Phase I 2021 Department of DefenseOffice for Chemical and Biological Defense -
Bounding generalization risk for Deep Neural Networks
SBC: Euler Scientific Topic: NGA20A001Deep Neural Networks have become ubiquitous in the modern analysis of voluminous datasets with geometric symmetries. In the field of Particle Physics, experiments such as DUNE require the detection of particle signatures interacting within the detector, with analyses of over a billion 3D event images per channel each year; with typical setups containing over 150,000 different channels. In an ...
STTR Phase I 2020 Department of DefenseNational Geospatial-Intelligence Agency -
Marburg Virus Prophylactic Medical Countermeasure
SBC: Flow Pharma, Inc. Topic: CBD18A002Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Hybrid DNN-based Transfer Learning and CNN-based Supervised Learning for Object Recognition in Multi-modal Infrared Imagery
SBC: TOYON RESEARCH CORPORATION Topic: 1On this effort Toyon Research Corp. and The Pennsylvania State University are developing deep learning-based algorithms for object recognition and new class discovery in look-down infrared (IR) imagery. Our approach involves the development of a hybrid classifier that exploits both transfer learning and semi-supervised paradigms in order to maintain good generalization accuracy, especially when li ...
STTR Phase I 2018 Department of DefenseNational Geospatial-Intelligence Agency -
Algorithms for Look-down Infrared Target Exploitation
SBC: Signature Research, Inc. Topic: 1Signature Research, Inc. (SGR) and Michigan Technological University (MTU) propose a Phase I STTR effort to develop a learning algorithm which exploits the spatio-spectral characteristics inherent within IR imagery and motion imagery.Our archive of modelled and labeled data sets will allow our team to thoroughly capture the variable elements that will drive machine learning performance.The overall ...
STTR Phase I 2018 Department of DefenseNational Geospatial-Intelligence Agency -
Marburg Virus Prophylactic Medical Countermeasure
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense